• Penicillin G Sodium: Applied Workflows & Real-World Troubles

  2026-05-12

  Penicillin G Sodium’s inhibition of bacterial cell wall biosynthesis delivers reliable protection against Gram-positive contamination in cell-based and microbiological research. Discover how APExBIO’s high-purity formulation enables robust experimental workflows, with evidence-backed parameters and troubleshooting strategies for reproducible results.

• Cisapride (R 51619) in Cardiac Electrophysiology Research

  2026-05-12

  Cisapride (R 51619) is a dual-action tool enabling precise interrogation of 5-HT4 receptor signaling and hERG channel inhibition in modern cardiac electrophysiology research. With validated solubility and purity, it empowers scalable, high-content phenotypic screening, uniquely supporting early-stage cardiotoxicity risk assessment.

• Antibacterial Drug Use and Resistance in Psychiatric Hospita

  2026-05-11

  This study provides a detailed analysis of antibacterial drug utilization and bacterial resistance patterns in a psychiatric hospital during the 2022 COVID-19 epidemic. The findings highlight both the rational use of third-generation cephalosporin antibiotics such as cefodizime and the ongoing challenge of managing antibiotic resistance in vulnerable patient populations.

• Carbapenemase Genes and Resistance Dynamics in CREC from Gua

  2026-05-11

  This study systematically characterizes the prevalence, genetic context, and transmission dynamics of carbapenemase-encoding genes (CEGs) in carbapenem-resistant Enterobacter cloacae (CREC) across eight teaching hospitals in Guangdong, China. The findings highlight the dominant role of plasmid-borne blaNDM-1 and the efficient horizontal transfer of multidrug resistance, with implications for molecular surveillance and clinical antimicrobial strategies.

• EdU Imaging Kits (Cy3): Next-Gen S-Phase DNA Synthesis Measu

  2026-05-10

  EdU Imaging Kits (Cy3) deliver denaturation-free, highly sensitive detection of cell proliferation, enabling robust S-phase quantification and advanced genotoxicity workflows. Their streamlined click chemistry protocol preserves cell morphology, making them indispensable for modern fluorescence microscopy and flow cytometry assays.

• Propranolol: Applied Workflows for Essential Tremor & Beyond

  2026-05-09

  Propranolol, an established non-selective β-adrenergic receptor blocker, empowers research in cardiovascular regulation and emotional memory modulation while setting the benchmark for essential tremor therapy. This guide distills cutting-edge experimental insights and troubleshooting strategies to maximize reproducibility and translational impact using APExBIO’s Propranolol.

• Ultra Fast LC–MS/MS for Cefazedone & Etimicin: PK Study Insi

  2026-05-08

  This study introduces a validated ultra fast LC–MS/MS method for simultaneous quantification of cefazedone and etimicin in beagle dog plasma. The approach enabled robust pharmacokinetic profiling of combination therapy, revealing no significant PK interactions and providing a critical tool for future translational antibiotic research.

• Neomycin Sulfate: Aminoglycoside Antibiotic in RNA/DNA Resea

  2026-05-08

  Neomycin sulfate enables robust mechanistic studies by stabilizing nucleic acid structures and modulating ion channels. This guide details workflow optimizations, troubleshooting tactics, and translational applications for advanced molecular biology projects.

• Sisomicin’s In Vitro Activity vs. Clinical Isolates: Lessons

  2026-05-07

  Stewart and Bodey's landmark study systematically compared the in vitro antibacterial activity of sisomicin to that of gentamicin, tobramycin, and other aminoglycosides against a wide panel of clinical Gram-negative and Gram-positive isolates. Their results highlight both the subtle potency differences and the resistance overlap among aminoglycoside antibiotics, informing the design and interpretation of contemporary microbiology research protocols.

• Metabolomics Reveals Carbapenem Resistance in Enterobacteral

  2026-05-07

  This study applies LC-MS/MS metabolomics to differentiate carbapenemase-producing Enterobacterales from non-resistant strains by metabolic signature, enabling rapid phenotyping under antibiotic-free conditions. The identified biomarkers and pathway alterations offer actionable insights for developing diagnostic assays and understanding resistance mechanisms.

• Synergistic Gamithromycin-Colistin Therapy Against P. multoc

  2026-05-06

  This study demonstrates that combining Gamithromycin with colistin markedly increases antimicrobial efficacy against Pasteurella multocida in a neutropenic murine lung infection model. The findings provide quantitative evidence for synergy, notably reducing required dosages and informing future therapeutic strategies for treatment of bovine respiratory disease and related infections.

• Cefodizime: Third-Generation Cephalosporin Antibiotic in Res

  2026-05-06

  Cefodizime empowers infection modeling with robust, broad-spectrum activity and unique immunomodulatory benefits, making it an essential tool for microbiology and translational workflows. This guide distills evidence-based protocols, troubleshooting strategies, and real-world insights—anchored by recent resistance monitoring studies—to maximize research impact.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial W

  2026-05-05

  Temafloxacin empowers researchers with reliable, scalable protocols for Gram-positive, Gram-negative, and intracellular pathogen assays. Its high potency, intracellular activity, and robust pharmacokinetic profile set it apart for advanced antibacterial research and translational studies.

• Single-Dose Gepotidacin for Uncomplicated Gonorrhea: Phase 2

  2026-05-05

  This phase 2 clinical trial evaluated gepotidacin, a novel bacterial type II topoisomerase inhibitor, for single-dose oral treatment of uncomplicated urogenital gonorrhea. The study demonstrated ≥95% efficacy in eradicating Neisseria gonorrhoeae with a favorable safety profile, underscoring gepotidacin's potential as an alternative therapy amid rising antibiotic resistance.

• Ceftolozane-Tazobactam for Nosocomial Pneumonia: Innovation

  2026-05-04

  This article examines the recent findings on ceftolozane-tazobactam as a potent alternative for treating nosocomial pneumonia, especially against multidrug-resistant Pseudomonas aeruginosa. The study's molecular insights, clinical performance, and resistance implications are discussed alongside considerations for broader research contexts.

15008 records 1/1001 page Next 12345 下5页 Last page